

Special Issue

Clinical Trials for Diffuse Large B-Cell Lymphomas (DLBCL)

Message from the Guest Editor

In this Special Issue, original research articles and reviews are welcome. We accept studies showing meaningful but negative results. Research areas may include (but are not limited to) the following:

- Sequencing treatment regimens with novel immunotherapies.
- Novel drug combinations and their efficacy and side effect profiles.
- New paradigms for the incorporation of radiotherapy.
- Management of emerging side effects from novel therapies (with a particular focus on prolonged cytopenias, cognitive changes, immunosuppression and associated infections).
- Treatment paradigms for underserved subtypes of DLBCL (e.g., primary CNS lymphoma, primary vitreo-retinal lymphoma, transformed marginal zone lymphoma, Richter's syndrome).
- Use of novel therapies in elderly patients.
- Integration of novel diagnostic tests (e.g., ctDNA) in treatment decisions.
- Use of novel biomarkers for treatment selection and personalized medicine approaches.
- Challenges in clinical trial management, including administrative burdens and updated good clinical practice guidelines.
- Applications of novel computational tools and artificial intelligence in clinical trial management.

Guest Editor

Dr. Erel Joffe

Lymphoma Service, Department of Medicine, Tel Aviv Medical Center,
Tel Aviv, Israel

Deadline for manuscript submissions

1 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/221498

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)